Patents by Inventor Gilles Raphy

Gilles Raphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histone deacetylase inhibitors and compositions and methods of use thereof
    Patent number: 10457675
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 29, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190062321
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.
    Type: Application
    Filed: July 30, 2018
    Publication date: February 28, 2019
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Histone deacetylase inhibitors and compositions and methods of use thereof
    Patent number: 10105363
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 23, 2018
    Assignee: CHDI foundation, Inc.
    Inventors: Celia Dominguez, Vahri Beaumont, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • Histone deacetylase inhibitors and compositions and methods of use thereof
    Patent number: 10065948
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 4, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Histone deacetylase inhibitors and compositions and methods of use thereof
    Patent number: 9783488
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 10, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Michel Maillard, Gilles Raphy, Alan F. Haughan, Christopher A. Luckhurst, Rebecca E. Jarvis, Roland W. Bürli, Perla Breccia, Grant Wishart, Samantha J. Hughes, Daniel R. Allen, Stephen D. Penrose
  • HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170224684
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Application
    Filed: January 20, 2017
    Publication date: August 10, 2017
    Inventors: Celia Dominguez, Vahri Beaumont, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170101402
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 13, 2017
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Roland W. Bürli, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebeca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Histone deacetylase inhibitors and compositions and methods of use thereof
    Patent number: 9562021
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 7, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Vahri Beaumont, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160039745
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 11, 2016
    Inventors: Celia Dominguez, Ignacio Muñoz-San Juan, Michel Maillard, Gilles Raphy, Alan F. Haughan, Christopher A. Luckhurst, Rebecca E. Jarvis, Roland W. Burli, Grant Wishart, Samantha J. Hughes, Daniel R. Allen, Stephen D. Penrose, Perla Breccia
  • HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160024019
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 28, 2016
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Vahri Beaumont, Maria Beconi, Roland W. Bürli, Alan F. Haughan, Christopher A. Luckhurst, Michael Wall, Gilles Raphy, Beth Thomas
  • Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
    Patent number: 8957090
    Abstract: A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: February 17, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Gilles Raphy, Roland Bürli, Alan Findlay Haughan
  • Triazine derivatives as kinase inhibitors
    Patent number: 8785628
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 22, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Quinoline derivatives as kinase inhibitors
    Patent number: 8653105
    Abstract: A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: February 18, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Quinoline derivatives as kinase inhibitors
    Patent number: 8637543
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Quinoline and Quinoxaline Derivatives as Kinase Inhibitors
    Publication number: 20130018057
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 17, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Roland Bürli, Alan Findlay Haughan, Mîzio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Quinoline and Quinoxaline Derivatives as Kinase Inhibitors
    Publication number: 20130012517
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 10, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors
    Publication number: 20130012515
    Abstract: A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 10, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Gilles Raphy, Roland Bürli, Alan Findlay Haughan
  • Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors
    Publication number: 20120095005
    Abstract: A series of substituted pyrazolo[1,5-?][1,3,5]triazine and pyrazolo[1,5-?j-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).
    Type: Application
    Filed: May 19, 2010
    Publication date: April 19, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Barry John Langham, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors
    Publication number: 20120077815
    Abstract: A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: February 11, 2010
    Publication date: March 29, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Triazine Derivatives as Kinase Inhibitors
    Publication number: 20120053167
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: March 2, 2010
    Publication date: March 1, 2012
    Applicant: UCB PHARMA, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe